InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
67,168.85
(
0.68%
)
Post# of 97239
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

barefootrunner

Send PM Follow Ignore
Followers 303
Posts 4680
Boards Moderated 0
Alias Born 11/26/2009

barefootrunner

Re: None

Thursday, 12/15/2011 9:24:25 AM

Thursday, December 15, 2011 9:24:25 AM

Post# of 97239
AIS - YM Biosciences valuation attractive, says Roth Capital
Roth Capital believes that YM Biosciences is well-positioned to sign a major partnership deal in 1H12, and the firm doesn't think that the differentiated CYT387 myelofibrosis data at ASH has been priced into the stock. The firm thinks that YM is a "compelling story," and it reiterates a Buy rating

Visit us at the $heff $tation

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up